AGIO Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Agios Pharmaceuticals, Inc. had $54.0M of revenue in fiscal 2025, up 48.0% on the year before.
Last close Β· Oct 23, 2026
$37.00
0.5%Hi! I read Agios Pharmaceuticals, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+48.0%
Yes. Sales grew 48.0% last year.
Does it make a profit?
β764.0%
No. It lost money last year.
Does profit turn into cash?
β698.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Agios Pharmaceuticals, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
November 5, 2026
Thursday Β· in 10 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 30, 2026 | Q2 '26 | Before the market opens | 8-K β |
| Apr 29, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Feb 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Oct 30, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Jul 31, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 1, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Feb 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 31, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Agios Pharmaceuticals, Inc. had $54.0M of revenue in fiscal 2025, up 48.0% on the year before. Its operating margin was β873.9%, up 292.6Β pts: of every 100 in sales, about β874 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Agios Pharmaceuticals, Inc. lost $413M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$377M in fiscal 2025, β698.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $4.8M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$4.8M
8 insiders
Of sales under plans
97%
$4.6M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 22, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 500 | $37.52 | $0.0M | Form 4 |
| Oct 21, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 1,489 | $37.53 | $0.1M | Form 4 |
| Aug 4, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 30,000 | $30.48 | $0.9M | Form 4 |
| Jul 1, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 4,007 | $37.56 | $0.2M | Form 4 |
| Apr 2, 2026 | Tsveta MilanovaChief Commercial Officer | Sold plan | 3,262 | $34.71 | $0.1M | Form 4 |
| Apr 2, 2026 | Brian GoffChief Executive Officer, Director | Sold plan | 19,068 | $34.71 | $0.7M | Form 4 |
| Apr 2, 2026 | Cecilia JonesChief Financial Officer | Sold plan | 3,141 | $34.71 | $0.1M | Form 4 |
| Apr 2, 2026 | James William BurnsChief Legal Officer | Sold plan | 3,280 | $34.71 | $0.1M | Form 4 |
| Apr 2, 2026 | Krishnan ViswanadhanChief Corp Dev & Strategy | Sold plan | 2,959 | $34.71 | $0.1M | Form 4 |
| Apr 2, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 2,940 | $34.71 | $0.1M | Form 4 |
| Mar 5, 2026 | Krishnan ViswanadhanChief Corp Dev & Strategy | Sold plan | 2,959 | $27.80 | $0.1M | Form 4 |
| Mar 3, 2026 | Theodore James Washburn Jr.Principal Accounting Officer | Sold | 5,272 | $28.88 | $0.2M | Form 4 |
| Mar 2, 2026 | Brian GoffChief Executive Officer, Director | Sold plan | 18,055 | $28.96 | $0.5M | Form 4 |
| Mar 2, 2026 | Tsveta MilanovaChief Commercial Officer | Sold plan | 2,868 | $28.96 | $0.1M | Form 4 |
| Mar 2, 2026 | Theodore James Washburn Jr.Principal Accounting Officer | Sold plan | 2,223 | $28.96 | $0.1M | Form 4 |
| Mar 2, 2026 | Sarah GheuensChief Medical Officer | Sold plan | 2,868 | $28.96 | $0.1M | Form 4 |
| Mar 2, 2026 | James William BurnsChief Legal Officer | Sold plan | 4,031 | $28.96 | $0.1M | Form 4 |
| Mar 2, 2026 | Cecilia JonesChief Financial Officer | Sold plan | 5,035 | $28.96 | $0.1M | Form 4 |
| Jan 5, 2026 | Tsveta MilanovaChief Commercial Officer | Sold plan | 2,872 | $27.02 | $0.1M | Form 4 |
| Dec 30, 2025 | Sarah GheuensChief Medical Officer | Sold plan | 2,932 | $27.09 | $0.1M | Form 4 |
| Dec 30, 2025 | James William BurnsChief Legal Officer | Sold plan | 2,932 | $27.09 | $0.1M | Form 4 |
| Dec 30, 2025 | Tsveta MilanovaChief Commercial Officer | Sold plan | 2,932 | $27.09 | $0.1M | Form 4 |
| Dec 30, 2025 | Cecilia JonesChief Financial Officer | Sold plan | 2,932 | $27.09 | $0.1M | Form 4 |
| Dec 30, 2025 | Brian GoffChief Executive Officer, Director | Sold plan | 18,703 | $27.09 | $0.5M | Form 4 |
| Nov 12, 2025 | David ScaddenDirector | Sold plan | 200 | $43.84 | $0.0M | Form 4 |
| Nov 11, 2025 | Sarah GheuensChief Medical Officer | Sold plan | 2,454 | $43.78 | $0.1M | Form 4 |
| Oct 30, 2025 | Sarah GheuensChief Medical Officer | Sold plan | 200 | $43.81 | $0.0M | Form 4 |
| Oct 27, 2025 | Sarah GheuensChief Medical Officer | Sold plan | 3,302 | $43.92 | $0.1M | Form 4 |
| Oct 8, 2025 | David ScaddenDirector | Sold plan | 200 | $41.00 | $0.0M | Form 4 |
| Sep 30, 2025 | David ScaddenDirector | Sold plan | 200 | $40.00 | $0.0M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Agios Pharmaceuticals, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.0B | $783M | $777M | $894M | $854M |
| Current ratio | 17.8x | 13.3x | 12.3x | 11.9x | 11.5x |
| Quick ratio | 17.8x | 13.2x | 12.0x | 11.6x | 11.1x |
| Total assets | $1.4B | $1.2B | $937M | $1.7B | $1.3B |
| Total liabilities | $146M | $138M | $126M | $122M | $104M |
| Shareholders' equity | $1.3B | $1.1B | $811M | $1.5B | $1.2B |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Agios Pharmaceuticals, Inc. passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 8 | 4 / 8 | 4 / 8 | 3 / 7 | 4 / 7 | 2 / 7 | 3 / 8 | 2 / 8 | 2 / 8 |
| Accruals ratio | β38.3% | β4.8% | β5.6% | β4.7% | β4.2% | 175.7% | 5.8% | β5.1% | 81.8% | β2.7% |
| Altman Z'' | 1.72 | β2.35 | 1.17 | β1.43 | β4.60 | 11.58 | 9.11 | 6.45 | 14.71 | 12.52 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $69.9M | $43.0M | $94.4M | $118M | $0.0M | $0.0M | $14.2M | $26.8M | $36.5M | $54.0M |
| Gross profit | $69.9M | $43.0M | $93.0M | $117M | $0.0M | $0.0M | $12.5M | $23.9M | $32.3M | $47.7M |
| Research and development | $220M | $293M | $341M | $214M | $221M | $257M | $280M | $296M | $301M | $340M |
| Operating income | β$201M | β$321M | β$362M | β$316M | β$336M | β$378M | β$389M | β$391M | β$426M | β$472M |
| Pretax income | β$198M | β$315M | β$346M | β$301M | β$329M | β$357M | β$232M | β$352M | $718M | β$414M |
| Income tax | $0.0M | $0.0M | $0.0M | $0.0M | β | β | $0.0M | $0.0M | $44.2M | β$1.0M |
| Net income | β$198M | β$315M | β$346M | β$411M | β$327M | $1.6B | β$232M | β$352M | $674M | β$413M |
| Diluted EPS | β$5.07 | β$6.75 | β$6.03 | β$6.86 | β$4.74 | $26.55 | β$4.23 | β$6.33 | $11.64 | β$7.12 |
| Diluted shares | 0.04B | 0.05B | 0.06B | 0.06B | 0.07B | 0.06B | 0.05B | 0.06B | 0.06B | 0.06B |
| Cash flow | ||||||||||
| Cash from operations | $38.6M | β$285M | β$304M | β$371M | β$291M | β$407M | β$309M | β$296M | β$390M | β$373M |
| Capital expenditure | $9.9M | $4.6M | $7.0M | $12.0M | $14.1M | $5.7M | $4.9M | $1.0M | $1.7M | $4.3M |
| Free cash flow | $28.6M | β$290M | β$311M | β$383M | β$305M | β$413M | β$314M | β$297M | β$392M | β$377M |
| Depreciation and amortization | $5.7M | $6.4M | $7.2M | $8.1M | $9.4M | $8.8M | $8.4M | $6.6M | $5.7M | $5.2M |
| Stock-based compensation | $42.1M | $47.8M | $73.4M | $58.1M | $61.6M | $53.5M | $49.3M | $44.8M | $42.8M | $52.6M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $541M | $103M | $585M | $565M | $573M | $1.0B | $783M | $777M | $894M | $854M |
| Current assets | $560M | $445M | $614M | $612M | $637M | $1.1B | $833M | $834M | $966M | $942M |
| Current liabilities | $88.4M | $94.9M | $93.5M | $92.9M | $94.4M | $59.8M | $62.6M | $68.0M | $81.2M | $82.2M |
| Inventory | β | $0.0M | $0.9M | $7.3M | $14.7M | $0.0M | $8.5M | $19.1M | $27.6M | $32.9M |
| Property and equipment, net | $25.3M | $24.4M | $24.3M | $31.5M | $30.8M | $28.9M | $23.0M | $15.4M | $11.7M | $10.8M |
| Total assets | $619M | $614M | $858M | $891M | $853M | $1.4B | $1.2B | $937M | $1.7B | $1.3B |
| Total liabilities | $261M | $239M | $171M | $250M | $453M | $146M | $138M | $126M | $122M | $104M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β |
| Shareholders' equity | $359M | $376M | $688M | $641M | $400M | $1.3B | $1.1B | $811M | $1.5B | $1.2B |
| Margins | ||||||||||
| Gross margin | 100.0% | 100.0% | 98.5% | 98.9% | β | β | 88.0% | 89.3% | 88.6% | 88.3% |
| Operating margin | β287.6% | β745.8% | β384.0% | β268.2% | β | β | β2,732.1% | β1,459.5% | β1,166.5% | β873.9% |
| EBITDA margin | β279.4% | β730.9% | β376.4% | β261.4% | β | β | β2,673.1% | β1,434.9% | β1,150.8% | β864.2% |
| Net margin | β284.0% | β731.6% | β366.6% | β349.0% | β | β | β1,627.8% | β1,312.6% | 1,845.9% | β764.0% |
| FCF margin | 41.0% | β673.9% | β329.9% | β324.5% | β | β | β2,207.6% | β1,107.5% | β1,072.7% | β698.3% |
| Returns | ||||||||||
| Return on capital employed | β37.9% | β61.8% | β47.4% | β39.6% | β44.3% | β27.5% | β33.1% | β45.0% | β26.9% | β38.9% |
| Return on equity | β55.3% | β85.7% | β65.1% | β62.0% | β63.0% | 189.7% | β19.4% | β36.8% | 57.3% | β30.2% |
| Return on assets | β32.1% | β51.0% | β47.0% | β47.0% | β37.5% | 140.1% | β17.3% | β32.4% | 51.8% | β27.9% |
| Return on tangible equity | β55.3% | β83.8% | β50.3% | β64.2% | β81.9% | 124.2% | β21.1% | β43.4% | 43.7% | β34.6% |
| Growth | ||||||||||
| Revenue growth | β | β38.5% | 119.4% | 24.9% | β100.0% | β | β | 88.4% | 36.1% | 48.0% |
| Net income growth | β | β | β | β | β | β | β114.4% | β | β | β161.3% |
| EPS growth | β | β | β | β | β | β | β115.9% | β | β | β161.2% |
| FCF growth | β | β1,111.8% | β | β | β | β | β | β | β | β |
| Share count change | β | 19.1% | 23.2% | 4.5% | 15.0% | β12.4% | β9.4% | 1.6% | 4.0% | 0.1% |
| Financial health | ||||||||||
| Current ratio | 6.3x | 4.7x | 6.6x | 6.6x | 6.7x | 17.8x | 13.3x | 12.3x | 11.9x | 11.5x |
| Quick ratio | 6.3x | 4.7x | 6.6x | 6.5x | 6.6x | 17.8x | 13.2x | 12.0x | 11.6x | 11.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 14.2% | 10.8% | 7.4% | 10.2% | β | β | 34.3% | 3.7% | 4.6% | 8.0% |
| Stock comp / revenue | 60.2% | 111.2% | 77.7% | 49.2% | β | β | 346.2% | 166.9% | 117.4% | 97.3% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 1.0 | 4.0 | 4.0 | 3.0 | 4.0 | 2.0 | 3.0 | 2.0 | 2.0 |
| Altman Z'' | 1.7 | β2.4 | 1.2 | β1.4 | β4.6 | 11.6 | 9.1 | 6.4 | 14.7 | 12.5 |
| Accruals ratio | β38.3% | β4.8% | β5.6% | β4.7% | β4.2% | 175.7% | 5.8% | β5.1% | 81.8% | β2.7% |
Source: SEC EDGAR XBRL filings (CIK 0001439222). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
